GENE ONLINE|News &
Opinion
Blog

2020-09-14| M&ATrials & Approvals

Gilead Strengthens its Oncology Portfolio with Acquisition of Immunomedics

by Judy Ya-Hsuan Lin
Share To

Gilead is ambitious in expanding its oncology portfolio, as it has made deals with three different pharmaceutical companies so far this year. Gilead recently acquired Immunomedics for $21 billion when the two parties signed a joint statement on September 13th.

By Judy Ya-Hsuan Lin

Months ago, Gilead purchased a 49.9% stake in cancer developer Pionyr Immunotherapeutics in June for $275 million and paid $4.9 billion for Forty Seven Inc. which is the creator of an experimental treatment targeting blood cancer. All these acquisitions give Gilead a strong foothold in the fast-growing cancer drug market.

On September 11th, Gilead offered about double the value of Immunomedics’s last closing price of $42.25 per share to acquire it for a total of $21 billion. The transaction is expected to close in the fourth quarter of this year, mainly granting Gilead access to Immunomedics’ breast cancer treatment drug Trodelvy. This acquisition aims to outcompete other large drug makers over securing the number of ownerships of oncology therapies in the portfolio. Also, breast cancer happens to be one of the most lucrative segments of the worldwide cancer therapy market. EvaluatePharma predicts that breast cancer therapy will make $157 million this year.

Related Article: Gilead Adds Jounce to its Long List of Oncology Partnerships

Gilead CEO, Daniel O’Day said, “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer.”

The future success of Trodelvy is optimistic, based on its past records. Trodelvy was granted an accelerated FDA approval in April and sparked $20.1 million net sales in its first two months on the market. According to Jefferies & Co. analytic firm, Trodelvy could become a go-to treatment for triple-negative breast cancer, and its sales will reach $480 million by 2022. According to the joint statement, in the first half of 2021, Immunomedicas will be on track to file for regulator approval for Trodelvy in Europe.

Gilead, Kite, and oNKo-innate Collaborate to Advance Cancer Immunotherapy Using NK Cells

References
  1. https://www.reuters.com/article/us-immunomedics-m-a-gilead-sciences/gilead-to-buy-immunomedics-in-21-billion-deal-idUSKBN2640V8

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
2023-07-28
Merger Announced Between Immunome and Morphimmune
2023-07-05
2023 ASCO Annual Meeting: Progress in Solid Tumor Treatment Research, and Promising Results in Emerging Therapies
2023-07-03
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top